BPC-157 is typically given as a small subcutaneous injection on a schedule your provider designs
In an extended review, it was highlighted that some preclinical gene-therapy approaches delivering exogenous antioxidant enzymes, via viral vectors or nanozyme platforms, in animal models of hyperglycemic bone defects, significantly reduced inflammation, limited ROS-mediated damage, and improved healing outcomes (Li et al., 2024)
This is oxidized by the peroxide to SeOH subsequently trapped by a GSH molecule to give Se-SG and by another GSH molecule to Se - again, releasing a GS-SG by-product
Aluminum chloride hydrate (7 mg/kg, Sigma-Aldrich Korea Ltd, Yongin, Korea) and oxaliplatin (3 mg/kg, Boryung Co., Ltd, Seoul, Korea) were injected according to the same schedule [33]